Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported that net product revenue from Iclusig sales came at $65.3 million in 2Q2016 against revenue of $27.8 million in the same period, a year earlier. Net product revenue includes one-time revenue of almost $25.5 million pertaining to collective shipments of Iclusig in France. This revenue was recorded upon getting reimbursement and pricing approval in May 2016.

The management speaks

Paris Panayiotopoulos, the CEO and President of Ariad, said that they reported a robust second quarter. In 2Q2016, they commenced a rolling NDA filing for brigatinib depending on company’s report from the ALTA pivotal study. They showcased 4-year data from the Iclusig PACE clinical study and strengthened overall financial position through deal with Incyte and the robust sales of Iclusig. The focus is now on Iclusig growth, planning for the projected launch of brigatinib in the United States and driving forward strong pipeline.

Business advancements

Earlier in June, Ariad closed the sale of its European businesses to Incyte Corporation. It also included sale of an exclusive license using which Incyte will market Iclusig in selected countries. The company received nearly $140 million for the deal and is also entitled to obtain 32% -50% of European future net sales. In addition, they closed two distribution deals for Iclusig outside of the United States.

In Latin America, the deal with Pint Pharma International S.A. includes Mexico, Colombia, Argentina, Brazil and Chile. In the MENA region, the deal with Biologix FZCo. includes Saudi Arabia, Lebanon, and the Gulf Coast nations and selected other nations in the region. Following these deals, Ariad will get over 50% of Iclusig future net sales.

The future plans

In June, Ariad detailed its plan to invest in anticipated new opportunities in field of immuno-oncology. The company has received pharmacologic and genetic validation on a preliminary target kinase, with the program projected to enter lead optimization by 2016.

Previous articleEvoke Pharma Inc (NASDAQ:EVOK) Schedules For A $10-Million Direct Offering At Market Prices
Next articleCalpine Corporation (NYSE:CPN) 2Q2016 Net Loss At $29 Million
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.